 BetterLife Pharma Inc. CSE:BETR, OTCQB:BETRF, a biotech company focused on the development of treatments for mental disorders, revealed that it has obtained the first set of neurological receptor functional binding data on its lead compound, 2-bromo-LSD TD-0148A. TD-0148A is a second-generation Lysergic Acid Diethylamide LSD derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing undesirable psychoactive dissociative side effects, such as hallucinations. 